Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA commissioner nominee questions do not address dietary supplement issues.

This article was originally published in The Tan Sheet

Executive Summary

PEDIATRIC INDICATIONS, CFC INHALERS AMONG OTC-RELATED ISSUES ADDRESSED in the list of questions forwarded by Senate Labor & Human Resources Committee Chairman James Jeffords (R-Vt.) to FDA Commissioner-nominee Jane Henney, MD, on July 31. The drug issues raised among the list of 140 questions posed in preparation for Henney's confirmation hearing focus almost exclusively on prescription concerns. However, there is overlap with OTCs on some issues, such as pediatric research requirements and the use of chlorofluorocarbons in metered-dose inhalers.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088734

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel